A feud between Prime Medicine and Tessera Therapeutics, two gene-editing companies, has spilled out into public.

On Monday, Prime Medicine Inc (PRME) stock saw a modest uptick, ending the day at $4.21 which represents a slight increase of $0.18 or 4.47% from the prior close of $4.03. The stock opened at $4.12 ...

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report), with a ...

A fierce rivalry is brewing between gene-editing companies Prime Medicine and Tessera Therapeutics. Jeremy Duffield, Prime’s ...

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report) today and set a price ...

ESGCT session on in vivo gene editing in preclinical model delivers new data from both Prime Medicine and Tessera ...

Ontario, Calif.-based Prime Healthcare's 2024 has been highlighted by plans to acquire nine Illinois hospitals and post-acute facilities from St. Louis-based Ascension and launching an integrated EMR ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Coronado Island Film Festival (CIFF) kicks off on Wed., Nov. 6, and has announced its 2024 Leonard Maltin Industry ...

Prime Minister Narendra Modi on Tuesday said in the past decade, India has witnessed the beginning of a new chapter in the health sector with the amalgamation of knowledge of Ayurveda with modern medi ...

Ian Higginson, vice-president of the Royal College of Emergency Medicine, said the current problems are not down to Covid or ...

British Prime Minister Keir Starmer says fixing Britain’s troubled economy will be a long haul in a “harsh” fiscal environment ...